Original ResearchClinical—Alimentary TractMaintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
Section snippets
Study Design and Patients
The study of infliximab diSconTinuation in CrOhn's disease patients in stable Remission on combined therapy with Immunosuppressors (STORI) was a prospective multicenter cohort study conducted at 20 centers in France and Belgium between March 2006 and December 2009. The study protocol and documents were approved by the Ethics Committee of the Saint-Louis Hospital in Paris on May 26, 2005. The investigational review board at each of the participating centers approved the protocol. All patients
Study Population
Between March 2006 and January 2008, 125 patients were prospectively recruited in 20 GETAID centers. The patients' flow diagram is shown in Figure 1. Ten patients with protocol violations as far as inclusion and/or exclusion criteria were not included in the analysis (detailed reasons for noninclusion are presented in the supplementary material). The demographic, clinical, biologic, and endoscopic characteristics of the 115 included patients at baseline are described in Table 1. Most patients
Discussion
In this study, about one-half of patients with Crohn's disease who were in corticosteroid-free remission with infliximab therapy over the last 6 months and with a combined antimetabolite agent for at least 1 year experienced a relapse within 1 to 2 years after discontinuation of infliximab. Several factors associated with a low risk of relapse were identified. Re-treatment of relapsing patients with infliximab was effective and well tolerated, at least in the short-term.
Stopping treatment with
Acknowledgments
Jean-Frédéric Colombel and Marc Lemann contributed equally to this work.
This study is registered at clinicaltrials.gov (NCT00571337).
The following GETAID Centers (investigators) participated in this study: Amiens (J. L. Dupas), Bordeaux (D. Laharie), Caen (J. M. Reimund), Clichy-Beaujon (Y. Bouhnik), Colombes-L Mourier (P. Jouet), Gent (M. De Vos), Liège (J. Belaiche, E. Louis), Lille (J.-F. Colombel, G. Vernier-Massouille), Lyon (S. Nancey), Marseille (J. C. Grimaud), Montpellier (M. Veyrac),
References (28)
- et al.
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Lancet
(2002) - et al.
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial
Gastroenterology
(2007) - et al.
Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis
Clin Gastroenterol Hepatol
(2009) - et al.
Risk factors for opportunistic infections in patients with inflammatory bowel disease
Gastroenterology
(2008) - et al.
Development of a Crohn's disease activity index
Gastroenterology
(1976) - et al.
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial
Gastroenterology
(2008) - et al.
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Clin Gastroenterol Hepatol
(2006) - et al.
Hydrocortisone intravenous premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial
Gastroenterology
(2003) - et al.
Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis
Joint Bone Spine
(2009) - et al.
Maintenance therapy with certolizumab pegol for Crohn's disease
N Engl J Med
(2007)
Economic implications of biological therapies for Crohn's disease: review of infliximab
Pharmacoeconomics
Cost-effectiveness of biological therapy for Crohn's diseaseMarkov cohort analyses incorporating United Kingdom patient-level cost data
Aliment Pharmacol Ther
Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy
Am J Gastroenterol
Development and validation of a Crohn's disease endoscopic index: a prospective multicentric study
Gut
Cited by (551)
Real-World Experience With Tofacitinib Dose De-Escalation in Patients With Moderate and Severe Ulcerative Colitis
2023, Clinical Gastroenterology and HepatologyThe Role of Noninvasive Surrogates of Inflammation in Monitoring Pediatric Inflammatory Bowel Diseases: The Old and the New
2023, Gastroenterology Clinics of North AmericaTreatment de-escalation in Crohn's disease
2023, The Lancet Gastroenterology and HepatologyTreatment de-escalation in Crohn's disease – Author's reply
2023, The Lancet Gastroenterology and HepatologyThe cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission
2023, The Lancet Gastroenterology and Hepatology
This article has an accompanying continuing medical education activity on page e31. Learning Objective: Upon completion of this exercise, successful learners will be able to assess the risk of relapse and the response to potential re-treatment in Crohn's disease patients in whom infliximab treatment would be stopped after prolonged stable remission under combined therapy with antimetabolite and infliximab.
Conflicts of interest The authors disclose the following: E.L. has received consultancy fees from Schering-Plough, Abbott Laboratories, MSD, Ferring Pharmaceuticals, Shire, Millennium Pharmaceuticals, and UCB; research or educational grants from MSD, Schering-Plough, AstraZeneca, and Abbott Laboratories; and lecture fees from Abbott Laboratories, AstraZeneca, Ferring Pharmaceuticals, MSD, Schering-Plough, Falk, Menarini, Chiesi, and Nycomed. Y.B. has received consultancy fees and lecture fees from Norgine, Abbott Laboratories, Schering-Plough, and Ferring Pharmaceuticals. D.L. has received consultancy fees from Norgine and Ferring Pharmaceuticals and has received lecture fees from Norgine, Ferring Pharmaceuticals, Abbott Laboratories, and Schering-Plough. G.S. has received lecture fees from Abbott Laboratories and Schering-Plough. M.D. has received an educational grant from Schering-Plough. G.P. has received consultancy fees from Roche and LFB and has received lecture fees from Janssen-Cilag. J.-F.C. has received consulting fees from Abbott Laboratories, ActogeniX, Albireo Pharma, Amgen, AstraZeneca, Bayer AG, Biogen Idec, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Cellerix, Centocor, ChemoCentryx, Cosmo Technologies, Danone Research, Elan Pharmaceuticals, Genentech, Giuliani SpA, Given Imaging, GlaxoSmithKline, Hutchison MediPharma, Merck Sharp & Dohme Corp, Millennium Pharmaceuticals (now Takeda), Neovacs, Ocera Therapeutics, Pfizer, Shire Pharmaceuticals, Prometheus Laboratories, Sanofi-Aventis, Schering-Plough, Synta Pharmaceuticals Corp, Teva, Therakos, UCB Pharma, and Wyeth; has served on advisory committees for Abbott Laboratories, Centocor, Danone Research, Elan Pharmaceuticals, Merck Sharp & Dohme, Millennium Pharmaceuticals (now Takeda), Schering-Plough, and UCB Pharma; has received speaking fees from Abbott Laboratories, Centocor, Elan Pharmaceuticals, Given Imaging, Merck Sharp & Dohme Corp, Otsuka America Pharmaceutical, Schering-Plough, Shire Pharmaceuticals, Tillotts Pharma, and UCB Pharma; and has received grant support from Abbott Laboratories, AstraZeneca, Ferring Pharmaceuticals, Merck Sharp & Dohme Corp, Schering-Plough, and UCB Pharma. The remaining authors disclose no conflicts.
Funding The GETAID received unrestricted study grants from the Association François Aupetit and the Société Nationale Française de Gastroentérologie.